Literature DB >> 28499724

Cardio-oncology in the older adult.

Prajwal Reddy1, Chetan Shenoy2, Anne H Blaes3.   

Abstract

Heart disease and cancer are the leading causes of death in older adults. Many first-line cancer treatments have the potential for cardiotoxicity. Age-related risk factors, pre-existing cardiac disease, and a high prevalence of comorbidities are reasons for increased cardiotoxicity in older adults. Concerns regarding cardiotoxicity may lead to frailty bias and undertreatment, resulting in suboptimal outcomes. There is an urgent need for geriatric-specific evidence and guidelines to help tailor care for this vulnerable group. A multi-disciplinary approach based on close collaboration between oncologists, cardiologists, and geriatricians, among other specialist clinicians is essential.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardio-oncology; Cardiotoxic treatments; Cardiotoxicity; Geriatrics; Older adult

Mesh:

Substances:

Year:  2017        PMID: 28499724      PMCID: PMC5776715          DOI: 10.1016/j.jgo.2017.04.001

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  85 in total

1.  Treatment patterns of elderly breast cancer patients at two Canadian cancer centres.

Authors:  F A Angarita; T Chesney; C Elser; A M Mulligan; D R McCready; J Escallon
Journal:  Eur J Surg Oncol       Date:  2015-02-07       Impact factor: 4.424

2.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

3.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.

Authors:  Pooja P Advani; Karla V Ballman; Travis J Dockter; Gerardo Colon-Otero; Edith A Perez
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

4.  Risk of cardiac death after adjuvant radiotherapy for breast cancer.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Jean L Freeman; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin
Journal:  J Natl Cancer Inst       Date:  2005-03-16       Impact factor: 13.506

5.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

6.  6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Authors:  Xavier Pivot; Gilles Romieu; Marc Debled; Jean-Yves Pierga; Pierre Kerbrat; Thomas Bachelot; Alain Lortholary; Marc Espié; Pierre Fumoleau; Daniel Serin; Jean-Philippe Jacquin; Christelle Jouannaud; Maria Rios; Sophie Abadie-Lacourtoisie; Nicole Tubiana-Mathieu; Laurent Cany; Stéphanie Catala; David Khayat; Iris Pauporté; Andrew Kramar
Journal:  Lancet Oncol       Date:  2013-06-11       Impact factor: 41.316

7.  Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).

Authors:  Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin
Journal:  J Geriatr Oncol       Date:  2015-10-30       Impact factor: 3.599

8.  Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.

Authors:  Ali Elitok; Fahrettin Oz; Ahmet Y Cizgici; Leyla Kilic; Rumeysa Ciftci; Fatma Sen; Zehra Bugra; Fehmi Mercanoglu; Aytac Oncul; Huseyin Oflaz
Journal:  Cardiol J       Date:  2013-10-21       Impact factor: 2.737

Review 9.  Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab.

Authors:  Gaurav Gulati; Kathleen W Zhang; Marielle Scherrer-Crosbie; Bonnie Ky
Journal:  Curr Heart Fail Rep       Date:  2014-12

10.  Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.

Authors:  Anne Polk; Nahid Shahmarvand; Kirsten Vistisen; Merete Vaage-Nilsen; Finn Ole Larsen; Morten Schou; Dorte Lisbeth Nielsen
Journal:  BMJ Open       Date:  2016-10-19       Impact factor: 2.692

View more
  4 in total

1.  Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin.

Authors:  Panagiotis Efentakis; Garyfalia Psarakou; Aimilia Varela; Eleni Dimitra Papanagnou; Michail Chatzistefanou; Panagiota-Efstathia Nikolaou; Costantinos H Davos; Maria Gavriatopoulou; Ioannis P Trougakos; Meletios Athanasios Dimopoulos; Ioanna Andreadou; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

2.  Cardiotoxicity among socioeconomically marginalized breast cancer patients.

Authors:  Yan Lu; Aaron W Gehr; Ifedioranma Anikpo; Rachel J Meadows; Kevin J Craten; Kalyani Narra; Anuradha Lingam; Sandeep Kamath; Bhavna Tanna; Bassam Ghabach; Rohit P Ojha
Journal:  Breast Cancer Res Treat       Date:  2022-08-15       Impact factor: 4.624

3.  Anthracycline chemotherapy-mediated vascular dysfunction as a model of accelerated vascular aging.

Authors:  Zachary S Clayton; David A Hutton; Sophia A Mahoney; Douglas R Seals
Journal:  Aging Cancer       Date:  2021-06-22

4.  Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.

Authors:  Miguel J Gil-Gil; Meritxell Bellet; Milana Bergamino; Serafín Morales; Agustí Barnadas; Luís Manso; Cristina Saura; Adela Fernández-Ortega; Elena Garcia-Martinez; Noelia Martinez-Jañez; Mireia Melé; Patricia Villagrasa; Pamela Celiz; X Perez Martin; Eva Ciruelos; Sonia Pernas
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.